相关实验视频
Updated: Jan 28, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.7K
慢性病中的巴里西提尼布:一个探索性分析,整合了网络毒理学,分子对接和药物监测
Rubin Zheng1,2,3, Jing Lu4, Miao Deng1,2
1Department of Nephrology, Qianxinan Affiliated Hospital of Zunyi Medical University, Xingyi, Guizhou, China.
Frontiers in medicine
|January 26, 2026
概括
巴里西提尼布通过向纤维化途径,显示出治疗慢性病 (CKD) 的潜力. 现实世界的数据证实了感染和血栓形成的风险,但没有损伤,支持进一步的CKD试验.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 计算生物学 计算生物学
背景情况:
- 慢性病 (CKD) 构成了全球卫生挑战,有效的抗纤维性疗法有限.
- 巴里西提尼布是一种JAK1/JAK2抑制剂,具有抗炎和抗纤维性质,但其在CKD中的作用需要研究.
研究的目的:
- 在慢性病 (CKD) 的背景下探索巴里西提尼布的机械基础和安全性.
- 评估巴里西提尼布对纤维化的潜在治疗作用,并评估现实世界的安全信号.
主要方法:
- 采用了综合网络毒理学,蛋白质-蛋白质相互作用网络分析和分子对接.
- 从FDA不良事件报告系统 (FAERS) 报告 (2018-2024) 中分析了现实世界的安全数据.
- 报告概率比率 (ROR) 和比例报告比率 (PRR) 被计算出来,以评估不良事件信号.
主要成果:
- 预测毒理学确定了潜在的呼吸道和急性毒性风险.
- 网络分析显示了核心枢纽的共享目标和高亲和性对接,表明路径调制 (JAK-STAT,MAPK,TGF-β/Smad3).
- FAERS分析显示感染和血栓栓塞事件的风险增加,但对脏不良事件没有不成比例的信号.
结论:
- 巴里西替尼在调节关键CKD路径方面显示出计算和机械潜力.
- 药监数据支持已知的风险 (感染,血栓形成),但没有表明不成比例的毒性.
- 这些发现支持通过前性,功能分层临床试验进一步研究慢性病中的巴里西提尼布.
更多相关视频
06:03Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
8.4K
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
1.2K
相关概念视频
01:25Chronic Kidney Disease I: Introduction
697
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
697
01:24Chronic Kidney Disease II: Clinical Manifestations
613
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
613
01:28Chronic Kidney Disease III: Interprofessional Care
387
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
387
01:18Chronic Kidney Disease IV: Nursing Management
363
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
363
01:19Pharmacovigilance
1.7K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.7K
01:22Chronic Obstructive Pulmonary Disease
2.5K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.5K